Why the study?
Should newer oral anticoagulants be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke?
Should newer oral anticoagulants be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke?
Answers are grounded in this paper and cite their sources.
The authors advocate for the use of newer oral anticoagulants as first-line agents for stroke prevention in patients with atrial fibrillation.
T he incidence of atrial fibrillation (AF) appears to be increasing, even after adjustment for aging of the population. Patients with AF have a 5-fold increased risk of stroke, and it is estimated that 15% to 20% of all strokes are attributable to AF. Moreover, death and disability from stroke complicating AF are particularly high. 3 Thus, stroke related to AF is a substantial and growing public health burden.
No takes yet. Share an insight, caveat, or question.
Granger et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: